The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
 
Chantale Bernatchez
Employment - Lexicon (I)
Stock and Other Ownership Interests - Lexicon (I)
Consulting or Advisory Role - Lion Biotechnologies
Research Funding - Idera; Nektar
Patents, Royalties, Other Intellectual Property - Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy
 
Cara L. Haymaker
Research Funding - Idera; Nektar
 
Michael E. Hurwitz
Employment - Pfizer (I)
Consulting or Advisory Role - Nektar
 
Harriet M. Kluger
Consulting or Advisory Role - Alexion Pharmaceuticals; Genentech/Roche; Prometheus; Regeneron
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Michael T. Tetzlaff
Consulting or Advisory Role - Myriad Genetics
 
Natalie Jackson
No Relationships to Disclose
 
Ivan Gergel
No Relationships to Disclose
 
Mary Ann Tagliaferri
No Relationships to Disclose
 
Jonathan Zalevsky
No Relationships to Disclose
 
Ute Hoch
Other Relationship - Nektar
 
Christie Fanton
Employment - Nektar
Stock and Other Ownership Interests - Nektar; Novartis
 
Ernesto Iacucci
No Relationships to Disclose
 
Sandra Aung
Employment - Nektar
Leadership - Nektar
Stock and Other Ownership Interests - Nektar
Travel, Accommodations, Expenses - Nektar
 
Michael Imperiale
No Relationships to Disclose
 
Ej Liao
Employment - Nektar; PRA Health Sciences
Stock and Other Ownership Interests - Nektar
 
Salah E Bentebibel
No Relationships to Disclose
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
 
Patrick Hwu
Stock and Other Ownership Interests - immatics; Lion Biotechnologies
Consulting or Advisory Role - Lion Biotechnologies
Research Funding - Genentech (Inst)
 
Mario Sznol
Stock and Other Ownership Interests - Adaptive Biotechnologies; Amphivena; Intensity Therapeutics
Consulting or Advisory Role - Adaptimmune; Agonox; Alexion Pharmaceuticals; Amgen; Anaeropharma; Astellas Pharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Genentech/Roche; Immune Design; Immune Design; Inovio Pharmaceuticals; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Lion Biotechnologies; Lycera; Merck Sharp & Dohme; Merus; Modulate Pharma; Nektar; Novartis; Omniox; pfizer; Prometheus; Seagen; Symphony Evolution; Theravance; Vaccinex
Other Relationship - AcademicCME; Clinical Care Options; Dava Oncology; Haymarket Media; Imedex; Physicans' Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico
 
Adi Diab
Consulting or Advisory Role - Celgene; CureVac; Nektar
Research Funding - Celgene (Inst); Idera (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar